Compare Modine Manufacturing Company (MOD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs Tango Therapeutics Inc. — how do they compare? Modine Manufacturing Company trades at $155 (market cap $9.17B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Modine Manufacturing Company is far larger — about 2.4× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Modine Manufacturing Company for 33 Days and Tango Therapeutics Inc. for 0 Days on average.
| MOD | TNGX | |
|---|---|---|
Market Cap | $9.17B | $3.75B |
Volume | 1,397,357 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $283.95 | $32.90 |
52-Week Low | $110.73 | $7.50 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $9.60B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing (MOD) trades at $172.57, showing minimal daily change. The stock exhibits a bearish technical signal with strong selling pressure on moving averages, though oscillators are neutral. Fundamentally, the company reported revenue of $2.58 billion in 2025 with a net income of $184 million, but profit margins are expected to compress in 2026. Recent corporate actions include the completion of a $946 million spin-off of its Performance Technologies unit with Gentherm, marking a strategic shift.
The outlook is mixed: strong analyst consensus with a $331.25 price target suggests significant upside, but near-term risks include margin pressure and bearish technical trends. Investment opportunity hinges on successful execution post-spin-off and data center cooling growth, while volatility from restructuring and market sentiment poses risks.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
